分化型甲状腺癌的再分化:一项叙述性文献综述的临床见解
该叙述性综述检索多个电子数据库,纳入2010年后发表的14篇英文文献,汇总再分化药物在放射性碘难治性转移性分化型甲状腺癌患者中的应用。初步数据显示,部分药物可能帮助特定患者重新建立131I摄取或增强摄取,从而可能提高每单位131I活度所递送的吸收剂量,并可能增加更好疗效的可能性或减少原计划131I活度。需进一步研究确认这些初步观察及再分化后可接受的后续131I治疗反应。
要点
- 再分化旨在重新建立131I摄取,使放射性碘难治性转移性分化型甲状腺癌患者可能再次接受131I治疗。
- 部分药物可能增强已有131I摄取患者的摄取,可能提高每单位131I活度的吸收剂量。
- 上述为初步数据,需进一步研究确认再分化后可接受的后续131I治疗反应。
核心结论
- 初步数据提示,特定药物可能为放射性碘难治性转移性分化型甲状腺癌的特定患者(如诊断性和/或治疗后放射性碘扫描阴性者)重新建立131I摄取提供可能。
- 这些药物也可能增强诊断性和/或治疗后放射性碘扫描显示有131I摄取的转移性分化型甲状腺癌患者的摄取。
- 这可能提高每单位131I活度所递送的吸收剂量,从而可能增加原计划131I活度获得更好疗效的可能性,或减少原计划131I活度同时达到相同预期疗效且潜在不良反应更少。
- 需进一步研究确认这些初步观察及再分化后和/或摄取增强后可接受的后续131I治疗反应。
研究设计与样本
- 叙述性综述,检索多个电子数据库,纳入2010年后发表的14篇相关英文文献。
主要发现
- 部分药物可能为放射性碘难治性转移性分化型甲状腺癌的特定患者重新建立131I摄取。
- 这些药物也可能增强已有131I摄取患者的摄取。
- 上述作用可能提高每单位131I活度所递送的吸收剂量,并可能增加更好疗效的可能性或减少原计划131I活度。
局限性
- 原文为叙述性综述,纳入14篇文献。
- 原文结论称上述为初步数据,需进一步研究确认这些初步观察及再分化后和/或摄取增强后可接受的后续131I治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Patients who have metastatic differentiated thyroid cancer (mDTC) frequently have negative diagnostic and/or post-therapy radioiodine scans. As a result, 131I therapy is frequently no longer considered a therapeutic option for these patients. However, with the knowledge of genomic alterations of patients with mDTC, the use of selected agents in specific patient groups may be used with the intention to re-establish 131I uptake (i.e., redifferentiation) and additional 131I therapy. The objectives of this narrative review are to present definitions of related terminology, a brief overview of the molecular mechanisms of redifferentiating agents, and a narrative review of the literature for redifferentiation in patients who have radioiodine refractory mDTC. Summary: We searched multiple electronic databases and reviewed the relevant English-language literature reported after 2010. Fourteen articles were included in this narrative review. Conclusions: Preliminary data suggest that select agents may offer potential for re-establishing 131I uptake in selected patients with radioiodine refractory mDTC (e.g., negative diagnostic and/or post-therapy radioiodine scans). These agents may also enhance uptake (e.g., uptake enhancement) in patients who have 131I uptake in mDTC on a diagnostic and/or post-therapy radioiodine scan. As a result, this may facilitate higher absorbed dose delivered (Gy (rad]) per 131I activity administered [GBq (mCi)]. This in turn may increase the likelihood of a better therapeutic effect for the planned administered 131I activity or a reduction in the originally planned administered 131I activity, while achieving the same intended therapeutic effect with potentially less untoward effects. Further studies are warranted to confirm these preliminary observations and to confirm acceptable subsequent 131I therapy responses after redifferentiation and/or uptake enhancement.
引用
- Van Nostrand D, Veytsman I, Kulkarni K, et al. Redifferentiation of Differentiated Thyroid Cancer: Clinical Insights from a Narrative Review of Literature. Thyroid. 2023. PMID: 36792922. doi:10.1089/thy.2022.0632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。